{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:35:54Z","timestamp":1779392154459,"version":"3.53.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chronic osteomyelitis is a serious osteoarticular infection that most often occurs in the long bones, responsible for significant morbidity with the risk of fracture and amputation. Despite advances in both antibiotics and surgical treatment, the probability of recurrence of infection remains at around 20%. Cerament-G (BONESUPPORT AB, Sweden) is a synthetic bone substitute that fills the bone void left by surgery, prevents infection and promotes bone regeneration within this space. Cerament-G also provides the local delivery of high doses of gentamicin over several weeks. Two prospective observational studies described a number of infectious recurrences of 4 and 5% after the use of Cerament-G. Although available in France, Cerament-G is currently not reimbursed and its high cost constitutes a barrier to its use. We hypothesize that the use of Cerament-G will lead to fewer costs to the collectivity while improving patient utility and, as an innovative strategy, will be superior to standard of care on recurrence of infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The Conviction Study is a prospective, multicenter, randomized, single blind study conducted in 14 French Reference Centers for Complex Osteoarticular infections. The main objective is to evaluate the cost-effectiveness of using Cerament-G in the treatment of chronic long bone osteomyelitis by comparing this innovative strategy to standard of care. A cost-utility analysis from the collective perspective will be conducted over a 24-month time horizon after the initial surgery. The outcome for the main medico-economic evaluation will be Quality Adjusted Life Years (QALYs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The study is being conducted throughout the CRIOAc network in France, in referral centers for the management of complex infections which will facilitate patient recruitment. This study has several limitations: the investigators have to be trained to handle the device, and it was impossible to blind the surgeon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>If the use of Cerament-G is demonstrated to be superior to leaving the dead space empty during surgery for patients with stage III chronic long bone osteomyelitis, its use will be recommended to improve the prognosis of such patients, and this device may eventually qualify for reimbursement through the French Health Insurance scheme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This protocol received authorization from the Ethics Committee CPP Sud M\u00e9diterran\u00e9e V on April 27, 2021 (21.03.10.77652) and the French National Agency for Medicines and Health Products on May 6, 2021 (2020-A02299-30). Results will be disseminated to the scientific community through congresses and publication in peer-reviewed journals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1116711","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T06:03:07Z","timestamp":1680156187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of a bone substitute delivering gentamicin in the treatment of chronic osteomyelitis of long bones: Protocol for the CONVICTION randomized multicenter study"],"prefix":"10.3389","volume":"10","author":[{"given":"Hassan","family":"Serrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Brosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Batailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7150\/jbji.31843","article-title":"Brodie's abscess: a systematic review of reported cases","volume":"4","author":"van der Naald","year":"2019","journal-title":"J Bone Joint Infect"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0002-9610(03)00292-7","article-title":"Surgical management of chronic osteomyelitis","volume":"188","author":"Parsons","year":"2004","journal-title":"Am J Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00402-019-03287-4","article-title":"General treatment principles for fracture-related infection: recommendations from an international expert group","volume":"140","author":"Metsemakers","year":"2020","journal-title":"Arch Orthop Trauma Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12879-018-3550-6","article-title":"Factors predictive of relapse in adult bacterial osteomyelitis of long bones","volume":"18","author":"Garcia Del Pozo","year":"2018","journal-title":"BMC Infect Dis"},{"key":"ref5","year":""},{"key":"ref6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/BOT.0b013e3181df91d9","article-title":"A prospective, randomized clinical trial comparing an antibiotic-impregnated bioabsorbable bone substitute with standard antibiotic-impregnated cement beads in the treatment of chronic osteomyelitis and infected nonunion","volume":"24","author":"McKee","year":"2010","journal-title":"J Orthop Trauma"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.7150\/jbji.23901","article-title":"Antibiotic containing bone substitute in major hip surgery: a long term gentamicin elution study","volume":"3","author":"Stravinskas","year":"2018","journal-title":"J Bone Joint Infect"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7150\/jbji.26301","article-title":"Antibiotic elution characteristics and pharmacokinetics of gentamicin and vancomycin from a mineral antibiotic carrier: an in vivo evaluation of 32 clinical cases","volume":"3","author":"Colding-Rasmussen","year":"2018","journal-title":"J Bone Joint Infect"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1302\/1358-992X.97BSUPP_16.EBJIS2015-103","article-title":"In-vivo gentamicin concentrations in plasma and drain fluid after bone defect reconstruction using a gentamicin-eluting bone graft substitute","author":"Horstmann","year":"2015","journal-title":"J Bone Joint Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1302\/0301-620X.98B9.38057","article-title":"Single-stage treatment of chronic osteomyelitis with a new absorbable, gentamicin-loaded, calcium sulphate\/hydroxyapatite biocomposite: a prospective series of 100 cases","author":"McNally","year":"2016","journal-title":"Bone Joint J"},{"key":"ref11","first-page":"21","article-title":"A comparative study of three bioabsorbable antibiotic carriers in chronic osteomyelitis: 313 patients with minimum 1 year follow-up","volume-title":"Orthop Procs","author":"McNally","year":"2015"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the global burden of disease 2013 study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Health"},{"key":"ref14","volume-title":"Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS","year":"2020"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40258-015-0161-x","article-title":"An estimation of the value of informal care provided to dependent people in Spain","volume":"13","author":"Oliva-Moreno","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40273-016-0468-y","article-title":"The valuation of informal Care in Cost-of-Illness Studies: a systematic review","volume":"35","author":"Oliva-Moreno","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00019053-200321050-00004","article-title":"Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease","volume":"21","author":"Wimo","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40258-018-0418-2","article-title":"Standardized questionnaire for the measurement, valuation, and estimation of costs of informal care based on the opportunity cost and proxy good method","volume":"17","author":"Landfeldt","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","article-title":"A French value set for the EQ-5D-5L","volume":"38","author":"Andrade","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref20","volume-title":"Choix m\u00e9thodologiques pour l\u2019analyse de l\u2019impact budg\u00e9taire \u00e0 la HAS","year":"2016"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"CD004439","DOI":"10.1002\/14651858.CD004439.pub3","article-title":"Antibiotics for treating chronic osteomyelitis in adults","volume":"6","author":"Conterno","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13690-017-0174-z","article-title":"Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium","volume":"75","author":"Maertens De Noordhout","year":"2017","journal-title":"Arch Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/v13122414","article-title":"Past and future of phage therapy and phage-derived proteins in patients with bone and joint infection","volume":"13","author":"Ferry","year":"2021","journal-title":"Viruses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5194\/jbji-7-169-2022","article-title":"Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis","volume":"7","author":"Karau","year":"2022","journal-title":"J Bone Joint Infect"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0076821","DOI":"10.1128\/AAC.00768-21","article-title":"Efficacy of Nanoencapsulated Daptomycin in an experimental methicillin-resistant Staphylococcus aureus bone and joint infection model","volume":"65","author":"Jacqueline","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"552669","DOI":"10.3389\/fmed.2021.552669","article-title":"Economic study of 2-stage exchange in patients with knee or hip prosthetic joint infection managed in a referral Center in France: time to use innovative(s) intervention(s) at the time of reimplantation to reduce the risk of superinfection","volume":"8","author":"Serrier","year":"2021","journal-title":"Front Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.otsr.2018.09.016","article-title":"The CRIOAc healthcare network in France: a nationwide health ministry program to improve the management of bone and joint infection","volume":"105","author":"Ferry","year":"2019","journal-title":"Orthop Traumatol Surg Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jinf.2020.12.010","article-title":"Epidemiology of complex bone and joint infections in France using a national registry: the CRIOAc network","volume":"82","author":"Lemaignen","year":"2021","journal-title":"J Infect"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1116711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T06:03:14Z","timestamp":1680156194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1116711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":28,"alternative-id":["10.3389\/fmed.2023.1116711"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1116711","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1116711"}}